Board of Directors
Dan Browne (Co-Founder, President & CEO of Revance Therapeutics, Inc.)
Bob Byrnes (Independent Director)
Mr. Byrnes has spent over thirty years in the medical device and biotech industry. Most recently from November 2002 to January 2005, he served as the President and Chief Executive Officer of Thermage, Inc. (“Thermage”), a medical device company focused on the non-invasive treatment of wrinkles. From October 1997 until October 2002 and from January 2005 to the present, Mr. Byrnes has served as the President and Chief Executive Officer of Roan, an advisory service for healthcare organizations. Mr. Byrnes has also served as Chairman and Chief Executive Officer of Tokos Medical, President of Caremark and Vice President of Marketing and Business Development for Genentech.
Ron Eastman (Essex Woodlands Health Ventures)
Mr. Eastman has over 30 years of experience in building healthcare businesses. He began his career at American Cyanamid Company, which was acquired by American Home Products (now Wyeth). At Cyanamid, Mr. Eastman spent 15 years managing various pharmaceutical products, divisions and subsidiaries in the U.S. and overseas. Since then, he has helped build three private healthcare companies -- Geron, HCORP, and Rinat Neuroscience. Under his leadership, Geron became a cutting-edge biotech company that grew from a venture-backed startup to a publicly traded pioneer in the fields of regenerative medicine and cancer. HCORP quickly established itself as the technology and market leader in the emerging field of hospital-based, interactive patient services and was sold to a diversified competitor. Most recently, at Rinat, a private biotech company spun out of Genentech in late 2001, Mr. Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat was acquired by Pfizer in 2006.
Phyllis Gardner, M.D., (Essex Woodlands Health Ventures)
Dr. Gardner has spent over 25 years in academia, medicine and industry. She began her academic medical career at Stanford University, where she has held several positions including Senior Associate Dean for Education and Student Affairs and remains today as Professor of Medicine. She took a leave of absence to work at ALZA Corporation, a major drug delivery company, as a Principal Scientist, Vice President of Research and as Head ofALZA Technology Institute. She has conducted extensive research in cell biology, including gene therapy, and is widely published in the fields of cell biology and pharmacology. She has received numerous national awards and honors and serves on the Board of Directors of several public and private companies. Dr. Gardner was responsible for Essex Woodlands’ introduction to Rinat Neurosciences, which was acquired by Pfizer, Inc. in April 2006.
Jim Glasheen, Ph.D. (Technology Partners)
Dr. Glasheen joined Technology Partners from CIT Venture Capital where he served as Managing Director, leading the Group's efforts in life science investing. Previously, he was a leader within McKinsey & Company's Pharmaceutical and Medical Products Practice. Over the course of several years, Dr. Glasheen worked extensively with a broad range life science companies on M&A, business development and strategic issues. Dr.Glasheen has published several papers and had his research highlighted in several major media outlets, including: Nature, The New York Times, Scientific American, CNN, Die Zeit, and Le Monde. He is on the Advisory Council of the Entrepreneurial Center at the University of California, Berkeley. Dr. Glasheen also serves as an advisor to the National Science Foundation’s (NSF) SBIR program in Washington D.C.
Frank Kung, Ph.D. (Vivo Ventures)
Dr. Kung is a founding member of Vivo Ventures, LLC. Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation which was acquired by its parent company in 1983. In 1984 he co-founded Genelabs Technologies, Inc. (NADSAQ:GNLB) where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public and built it to an international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan. Dr. Kung received the Best Use of Technology Award from the Governor of California, the Entrepreneur of the Year Awards from Ernst and Young, and the Asian Business League. He was also appointed by the U.S. Secretary of Health and Human Services as a voting member of the National Biotechnology Policy Board.
Vicente Trelles (Independent Director)
Mr. Trelles was Executive Vice President of INAMED Corporation from 2001 to March 2006. He was a senior member of the management team that created over $2.8 billion of shareholder value in four years. As Executive Vice President and Chief Operations Officer, Mr. Trelles was responsible for managing INAMED’s global operations including product development, quality systems, manufacturing, supply chain, regulatory compliance, and key strategic business partnerships. He has spent 24 years within the medical device and pharmaceutical industries managing global operations at INAMED, Allergan and Baxter Healthcare. Mr. Trelles was the Chief Operating Officer of McGhan Medical (a wholly owned subsidiary of INAMED) where he managed product development, clinical research, quality, regulatory affairs and compliance, manufacturing, supply chain information technology and distribution functions.
Jonathan Tunnicliffe (NovaQuest Capital Management)
Mr. Tunnicliffe has over 23 years of experience in the biopharmaceutical industry. From 2000, he was global head of due diligence for the NQ business unit of Quintiles. He also performed a leadership role in the ongoing management, origination, structuring and contracting of investments. Mr. Tunnicliffe was previously a founding member and Director of Operations of a specialized clinical research organization, S-Cubed where he led all operational functions. In Mr. Tunnicliffe’s earlier career, he was a medical statistician at SmithKline and French (now Glaxo SmithKline) and at the University of Sheffield. Mr. Tunnicliffe has a Bachelor’s degree in Mathematical Statistics from the University of Liverpool, a Master of Science in Medical Statistics from the University of Newcastle-upon-Tyne and an MBA from Sheffield Hallam University. He also holds a Postgraduate Diploma in Marketing from the Chartered Institute of Marketing in the United Kingdom.